New Funding Source for NIH Applicants

“Last year, U.S. researchers received about 42,500 pieces of bad news from the National Institutes of Health (NIH). Their grant proposal had been rejected; they wouldn’t be receiving a piece of the agency’s roughly $30 billion federal funding pie. For many, the next step is to cast around for slices of smaller pies—grants from nonprofit disease foundations or investments from private companies that might keep their projects alive.

Now, a new program aims to play matchmaker between these researchers and second-chance funders. The Online Partnership to Accelerate Research (OnPAR), a collaboration between NIH and the defense, engineering, and health contractor Leidos, lets researchers upload rejected NIH proposals to an online portal where potential funders can review the scores received from reviewers, and decide whether to put up cash.”

Read more online

 

Research for Lunch with Dr. Jae-Won Choi

Multi-scale 3D Printing of Microneedle Arrays for Early-Stage Melanoma Therapy

Dr. Jae-Won Choi

Monday, April 11, 2016

ASEC Room 105, from 12-1 pm

Dr. Jae-Won Choi is a tenure-track Assistant Professor in the Department of Mechanical Engineering at the University of Akron (UA).  Prior to joining UA in 2011, he spent one year for his Post-Doctoral research in the W.M. Keck Center for 3D Innovation at the University of Texas at El Paso (UTEP) in 2007, sponsored by the Overseas Post-Doctoral Fellowship from the Korea Research Foundations.  After his involvement with the W.M. Keck Center, he was promoted twice first to the rank of Research Specialist in 2008, and then to Research Assistant Professor in 2009.  Currently, he is serving as an editorial board member in several journals – Additive Manufacturing; Korean Society of Manufacturing Processing Engineers; and Korean Society of Mechanical Technology.  He is a member of ASME, SME, and SPIE.

Summary of Research

The goal of Dr. Choi’s research is to provide a 3D printing solution for the treatment of a skin cancer called “melanoma”. The advantage of 3D printing is quickly manufacturing patient specific, 3D micron-scale needle arrays loaded with the desired chemotherapeutic drugs with the appropriate dosage and duration of release. The 3D microneedle arrays will have therapeutic dosages to kill various melanomas by providing controlled and/or bolus release of drugs.